The α5 Subunit Regulates the Expression and Function of α4*-Containing Neuronal Nicotinic Acetylcholine Receptors in the Ventral-Tegmental Area

Susmita Chatterjee², Nathan Santos², Joan Holgate¹, Carolina L. Haass-Koffler²,³, F. Woodward Hopf²,⁶, Viktor Kharazia², Henry Lester⁴, Antonello Bonci⁵,⁶,⁷, Selena E. Bartlett¹∗

1 Translational Research Institute, Institute for Health and Biomedical Sciences, Faculty of Health, School of Clinical Sciences, Queensland University of Technology, Brisbane, Australia, 2 Ernest Gallo Clinic and Research Center at the University of California, San Francisco, Emeryville, California, United States of America, 3 Clinical Pharmacology and Experimental Therapeutics, School of Medicine, University of California, San Francisco, California, United States of America, 4 Division of Biology, California Institute of Technology, Pasadena, California, United States of America, 5 Intramural Research Program, National Institute on Drug Abuse, Baltimore, Maryland, United States of America, 6 Department of Neurology, University of California, San Francisco, California, United States of America, 7 Solomon Snyder Department of Neuroscience, Johns Hopkins University, Baltimore, Maryland, United States of America

Abstract

Human genetic association studies have shown gene variants in the α5 subunit of the neuronal nicotinic receptor (nAChR) influence both ethanol and nicotine dependence. The α5 subunit is an accessory subunit that facilitates α4* nAChRs assembly in vitro. However, it is unknown whether this occurs in the brain, as there are few research tools to adequately address this question. As the α4*-containing nAChRs are highly expressed in the ventral tegmental area (VTA) we assessed the molecular, functional and pharmacological roles of α5 in α4*-containing nAChRs in the VTA. We utilized transgenic mice a5+/+(a4YFP) and a5-/-/(a4YFP) that allow the direct visualization and measurement of α4-YFP expression and the effect of the presence (a5+/+) and absence of α5 (-/-) subunit, as the antibodies for detecting the α4* subunits of the nAChR are not specific. We performed voltage clamp electrophysiological experiments to study baseline nicotinic currents in VTA dopaminergic neurons. We show that in the presence of the α5 subunit, the overall expression of α4 subunit is increased significantly by 60% in the VTA. Furthermore, the α5 subunit strengthens baseline nAChR currents, suggesting the increased expression of α4* nAChRs to be likely on the cell surface. While the presence of the α5 subunit blunts the desensitization of nAChRs following nicotine exposure, it does not alter the amount of ethanol potentiation of VTA dopaminergic neurons. Our data demonstrates a major regulatory role for the α5 subunit in both the maintenance of α4*-containing nAChRs expression and in modulating nicotinic currents in VTA dopaminergic neurons. Additionally, the α5α4* nAChR in VTA dopaminergic neurons regulates the effect of nicotine but not ethanol on currents. Together, the data suggest that the α5 subunit is critical for controlling the expression and functional role of a population of α4*-containing nAChRs in the VTA.

Introduction

Neuronal nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels with a vast diversity of subtypes [1]. The different nAChR subtypes are made up of α₂,₃ and β₂,₄ subunits in the heteromeric form or α₅-₁₀ subunits in the homomeric form, where each subunit is encoded by a distinct gene [2,3]. The nAChRs are abundant in several brain areas including the ventral tegmental area (VTA) [4,5], which is part of the midbrain dopaminergic reward system [6,7]. The subunit composition of nAChR is dependent on the brain region and neuronal type [8–11]. The α4β2* (*denotes the possibility that other nAChR subunits are present in the pentameric nAChR), and α7 are the most highly expressed subtype in the brain [12,13]

A wide range of pharmacological compounds have been found to activate nAChRs [14]. The neurotransmitter acetylcholine (ACh) is an endogenous agonist that can bind...
and activate nAChRs [15]. ACh or an exogenous agonist such as nicotine has a distinct binding site that is different from allosteric modulators such as ethanol [14]. The pharmacological, Ca\(^{2+}\) permeability and desensitization properties of these ion channels to different agonists such as ACh, nicotine or ethanol are influenced by the subunit composition of the nAChR. For example the α4β2* compared to α7 nAChRs have a slower nicotinic current kinetics with reduced Ca\(^{2+}\) ion permeability and a stronger desensitization to nicotine [16–19].

Recent human genetic association studies identified variants in the CHRNA5 gene encoding the α5 nAChR subunit have the risk of developing ethanol or nicotine dependence [20–23]. Hence, the α5* nAChRs may be a promising target for alcohol and nicotine cessation therapy. The VTA plays a key role in the acquisition of behaviors reinforced by addictive drugs such as ethanol and nicotine [6,7], and both nicotine and ethanol can activate VTA neurons via nAChRs [24–26]. The VTA has a high concentration of the α4β2* nAChR subtype, predominantly found in dopaminergic and GABAergic neurons, and the α7 nAChRs on presynaptic glutamatergic terminals [24,27,28].

α5 is an accessory subunit that does not contribute to the formation of agonist binding site and is only co-expressed with other α and β nAChR subunits. It is present in high concentrations in the VTA, and is thought to be an important component of the putative functional (α4β2) α5 nAChR subtype expressed in this region [4,29]. Cell-based heterologous expression systems have been widely used along with recent animal behavioral studies to understand α5 nAChR pharmacology. The presence of α5 subunits in α4* nAChRs produces larger nicotinic currents and modifies ACh sensitivity of α4*-containing nAChRs in cultured neurons and prefrontal cortex [30–33]. Behaviorally, the α5 nAChR subunit has been strongly associated with nicotine’s effects in rodents, since α5-/- mice display altered anxiety-related behavior [34], low sensitivity to high doses of acute nicotine [35] and increased nicotine intake at very high aversive doses [36]. Recently, it was shown that α5 nAChR subunit is important for the sedative effects of ethanol but not consumption in mice (Santos et al., 2012). However, nothing is known so far about the expression and functional contribution of α5 for nicotine and ethanol in the ventral tegmental area of the brain.

Specific nAChR subunits have been impossible to visualize and quantify expression of in vivo because of the lack of subtype specific tools. Here, we have developed a novel mouse line by crossing α5 nAChR deficient mice with α4-YFP nAChR knock-in (KI) mice, allowing us to directly determine the role of α5 in regulating protein expression of α4*-containing nAChRs in the brain. We found α5 to play a key role in controlling the expression of α4*-containing nAChRs in the VTA that likely affects the strength of nicotinic receptor currents of VTA dopamine neurons studied here. Additionally, the presence of α5 appears to play no additional functional role in ethanol’s effect on nAChRs in ventral tegmental area.

Methods and Materials

Animals and Housing

All mice were housed in climate controlled rooms with food and water available ad libitum. Mice were housed 2-5 per cage on a 12 hour light/dark cycle (lights on 7am).

Ethical Considerations

The experiments contained herein comply with the laws of USA. All procedures were pre-approved by the Gallo Center ethics committee and were in accordance with NIH guidelines for the Humane Care and Use of Laboratory Animals.

α5 nAChR deficient mice

The α5-/- mice were generously provided by Dr. Jerry Stitzel (Institute for Behavioral Genetics, University of Colorado), and had been backcrossed at least 10 generations on a C57BL/6J background. The α5+/+ mice and α5-/-- littermate mice used here were generated from heterozygous breeding pairs. The α5-deficient mice have a healthy appearance and no abnormalities in a standard battery of behavioral tests [35].

α4YFP, α5+/+(α4YFP) and α5-/-(α4YFP) mice

The α4YFP knock-in mice (α4 nAChR subunit tagged with yellow fluorescent protein (YFP)) generated by the Lester Lab (Caltech) had been backcrossed on a C57BL/6J background for at least 10 generations [37]. The α4YFP mice retained the receptor function when fluorescent proteins were inserted into the intracellular M3-M4 intracellular loop of the α4 subunit. In addition, the tagged α4 nAChRs displayed similar localization patterns in the brain and are under the control of the same promoters, enhancers and trafficking mechanisms as the WT α4 [38]. Two further generations of backcrossing were performed after arrival. The mice used in this study were generated from homozygous breeding pairs. The α4-YFP mice have a healthy appearance and receptor function and have been shown to be similar to wild-type mice [38].

To be able to directly visualize and measure the contribution of α5 to α4 subunit regulation, α5+/+ and α5-/- mice were cross-bred with the α4YFP mice to create α5+/+(α4YFP) and α5-/-(α4YFP) mice. Homozygous α5-/- mice were bred with homozygous α4YFP mice to produce heterozygous α5+/-- heterozygous α4YFP mice. The male and female heterozygous α5+/-- and heterozygous α4YFP littermates were then mated. From these offspring heterozygous α5+/-- and homozygous α4YFP littermates were mated such that all offspring produced from these pairs possessed both α4YFP genes with only the number of α5 subunit genes varying between the offspring. The α5+/+(α4YFP) mice have a healthy appearance and did not appear to be different from α5-/-(α4YFP) mice. Genotyping for α5 nAChR-deficient, α4YFP, α5+/+(α4YFP) and α5-/-(α4YFP) mice was performed using polymerase chain reaction as previously described for the α5 gene [35] and the α4YFP gene [37].
Immunohistochemistry and Imaging

Male a5+/+(α4YFP) and a5-/-(α4YFP) mice (p35-p56 age) were deeply anesthetized with 200 mg/kg Euthasol® (Virbac, TX) and intracardially perfused with 0.9% NaCl, followed by 4% paraformaldehyde (Sigma-Aldrich, MO). Extracted brains were further fixed in 4% paraformaldehyde for 4 hours and 30% sucrose for 2 days. 50 µm frozen sections were prepared using a Microm cryostat (Thermo, Fisher Scientific, MA). Free-floating horizontal sections containing the VTA were stained with FITC-conjugated goat anti-GFP polyclonal antibody, also recognizing YFP (1:1000, ab6662, Abcam, MA) [39,40], mouse anti-Tyrosine Hydroxylase monoclonal antibody (1:2000, TH, Sigma-Aldrich, MO) followed by Alexa Fluor 594-labeled donkey anti-mouse secondary antibody (1:300, Invitrogen, CA) before mounting on slides. In addition to YFP and TH markers, we also performed triple-labeling experiments by adding a rabbit polyclonal antibody recognizing GAD65/67 (1:500; laser confocal microscope (Zeiss MicroImaging, Thornwood, NY). VTA images were taken using SDS-PAGE with 4-20% tris-glycine gels and transferred to nitrocellulose membranes (Pierce Protein Research Products, IL) followed by Alexa Fluor 594-conjugated donkey anti-rabbit secondary antibody, and the TH was visualized with Alexa Fluor 647-conjugated donkey anti-mouse secondary antibody. Images were acquired using a Zeiss LSM 510 META laser confocal microscope (Zeiss MicroImaging, Thornwood, NY, US) or Nikon Eclipse Ti-E Motorized Inverted Microscope (Nikon Instruments Inc, Melville, NY). VTA images were taken in areas similar to those used for electrophysiology immediately medial to the medial terminal nucleus of the accessory optic tract (MT) in primarily the more ventral sections containing the VTA (43). Images were processed using the Imaris Neuroscience software pack (v.7.1.1, Andor Technology, Belfast, Northern Ireland); the colocalization study for the YFP protein and the TH or GABA protein was performed using ImageJ plugins (v 1.43m) (NIH).

Western Blots

Preparation of homogenates. Brains were harvested from male a5+/+(α4YFP) and a5-/-(α4YFP) at p35-p70 age and 1 mm coronal sections were made using an ice cold brain matrix (Australian National University). Section(s) containing the VTA were placed on an ice cold platform and dissected under a microscope (Leica S6D, IL) and stored at -80°C. On the day of the analysis, VTA were thawed and then homogenized in lysis buffer (phosphate buffered saline containing 0.1% Triton-X and complete mini-protease inhibitor) with 0.5 mm glass beads using the Bullet Blender (Next Advance, NY) at 4°C. Protein concentration was determined using Bradford protein reagent (BioRad, CA) and the SpectroMax spectrophotometer (Molecular Devices, CA). Samples were diluted to the appropriate concentration (20 μg/ lane) in reducing sample buffer (Pierce Protein Research Products, IL) and incubated at 37°C for 30 min.

Protein separation and Analysis. Proteins were separated using SDS-PAGE with 4-20% tris-glycine gels and transferred under ice cold conditions to a nitrocellulose membrane. Membranes were blocked in phosphate-buffered saline containing 5% milk and 0.05% Tween 20 then probed with primary antibodies at 4°C overnight. Rabbit polyclonal antibody against GFP (1:2500, ab290, Abcam, MA) and mouse monoclonal anti-GAPDH antibody (1:10000, MA1-22670, Affinity Bioreagents Inc, CO) were used. Appropriate Dylight 800-conjugated secondary antibodies (1:10000, Rockland Immunocchemicals, PA) were used for band detection with the Odyssey Infrared Imaging System (LI-COR Biosciences, NE). Band densities were measured using Odyssey Application Software version 2.0.40 (LI-COR Biosciences, NE). An exclusion criterion was applied and α4-YFP expression levels of less than 1% of GAPDH were removed from both genotypes.

Electrophysiology

Male mice (P21-31) were deeply anesthetized and perfused transcardially with ~ 20 ml of ice-cold modified artificial cerebrospinal fluid (aCSF): 75 sucrose; 87 NaCl, 2.5 KCl, 1.25 NaH2PO4, 7 MgCl2, 0.5 CaCl2, 25 NaHCO3, saturated with 95% O2-5% CO2. Horizontal VTA brain slices (200 μm) were prepared in the same solution and recovered for at least 1hr at 31°C in aCSF, osmolarity 304-306, containing (in mM): 126 NaCl, 2.5 KCl, 1.1 NaH2PO4, 1.4 MgCl2, 2.4 CaCl2, 11 D-glucose and 26 NaHCO3 with ascorbic acid (1 mM) added just before the first slice.

Whole-cell voltage-clamp recordings made with Multiclamp 700B amplifier using Clampex 9.0 acquisition software (Molecular Devices, Sunnyvale) with acquisition rate of 10KHz and low-pass filtering at 2KHz. Experiments were performed on VTA dopaminergic neurons located immediately medial to the medial terminal nucleus (MT) of the accessory optic tract and identified by the detection of a large Ii current [41,42]. Recently, studies have shown that the presence of an Ii current does not unequivocally identify DA neurons [43]. We were consistent in our patching area where majority of Ii positive neurons are dopaminergic neurons (TH positive) [41,42]. Hence, it’s likely that the number of Ii positive TH negative neurons that contributed to this study is very small. Neurons were held at -70 mV and recordings made with 3-5 MO resistance patch-pipettes using a cesium-based internal solution containing: 117 mM cesium methanesulphonate, 20 mM HEPEs, 0.4 mM EGTA, 2.8mM NaCl, 5 mM TEA-Cl, 2.5mg/ml Mg-ATP and 0.25 mg/ml Mg-GTP, at pH=7.2-7.4 and osmolarity 280-285. The input resistance (Ri) and series resistance (Rs) were continuously monitored throughout the recording and cells with any large deviations of these properties were not included in the analysis. All pharmacological experiments included atropine (1 μM) in aCSF to block muscarinic acetylcholine receptors. Nicotinic currents were activated by pressure application of acetylcholine (ACh, 1 mM) via picospritzer pipettes (10 psi, Parker Hannifin Instrument, Cleveland, OH) (adapted from [18]). Neurons with stable holding current for 5 min were bathed with ACh estimated to be ~20 μM from the neuron for 300 ms every 2 min for 6 min. The average of the three peak inward currents (evoked every 2 min across 6 min) was taken to be the baseline was calculated relative to the holding current 500 ms immediately before the ACh puff using Clampfit 9.0 acquisition software (Molecular Devices, Sunnyvale, CA). A drug was then bath applied for 10 min during which time ACh was bath applied for 2 min followed by 10 min wash-out period. The amplitude of the ACh-induced current at each time point was measured as percent change of baseline current induced.
amplitude of ACh-induced baseline current) X 100. The drugs used here were nicotine (0.3 µM and 1 µM), ethanol (60 mM and 80 mM), dihydro-beta-erythroidine (DHβE, 2 µM), methyllycaconitine (MLA, 5 nM) or tetrodotoxin (2 µM). Only one drug concentration was applied per neuron. We observed a low incidence of fast nAChR currents which could be because of not using a computer-controlled motorized puffer that could be retracted after puffing. Hence, any agonist leakage could potentially cause a loss or underestimate the fast component elicited by mainly the α7 nAChR [18].

Drugs
The 95% (v/v) ethanol (Gold Shield Chemical Co, CA), nicotine hydrogen tartrate, atropine, DHβE, MLA, tetrodotoxin, acetylcholine chloride (Sigma-Aldrich, MO) solutions were prepared fresh daily for all experiments.

Statistics
We used Graph Pad Prism (Graph Pad, CA) or Sigma Stat (Systat Software, CA), using two-way, one-way ANOVA or unpaired t-test wherever applicable with Newman–Keuls post hoc analysis when a significant effect was found (p < 0.05).

Results
α5 subunits help maintain the expression of α4*-containing nAChR in the VTA
The α4*-containing nAChRs are highly expressed in the VTA [44]. The α5 functions as an accessory subunit and assembles predominantly with the α4*-containing nAChRs in the VTA [1,29]. We wanted to first examine whether the presence of α5 is critical for maintaining VTA α4 protein levels. Since visualization and quantification of nAChRs has been difficult due to lack of specific antibodies; we utilized transgenic mice in fertility and produced expected proportions of transgenic mice prepared fresh daily for all experiments.

Statistics
We used Graph Pad Prism (Graph Pad, CA) or Sigma Stat (Systat Software, CA), using two-way, one-way ANOVA or unpaired t-test wherever applicable with Newman–Keuls post hoc analysis when a significant effect was found (p < 0.05).

a5 nAChR Regulates α4 nAChR Expression in the VTA

Figure 1. The α5 subunit plays an important role in maintaining α4* nAChR levels. (A and B) The α5-/-(α4 YFP) mice have significantly reduced α4YFP expression levels in the VTA compared with α5+/+(α4 YFP) quantified using western blot analysis. The values are expressed as mean α4 YFP expression (% of GAPDH) ± SEM (two-tailed unpaired t-test, *p<0.05). n=6-8 number of animals (two-tailed unpaired t-test, *p<0.05).

doi: 10.1371/journal.pone.0068300.g001

where we performed electrophysiology in α5+/+(α4YFP) and α5-/-(α4YFP) mice showed that α4YFP is co-expressed in the majority of TH-positive dopaminergic neurons in both genotypes (Figure 2A & B) (α5+/+(α4YFP): n=2 animals; α5-/-(α4YFP): n=3 animals). Triple-staining with antibodies against GFP (YFP), GAD65/67 (GABAergic marker) and TH shows that GAD65/67-positive perikarya express much less YFP than adjacent TH-positive dopaminergic cells which extend the data previously described by (Nashmi et al., 2007) (38) (Figure 2C).

α5 subunits enhance the strength of α4* nicotinic currents in VTA dopaminergic neurons
To assess the functional effect of reduced α4 protein levels, we examined here the nAChR activation of dopaminergic neurons in VTA brain slices from α5+/+ and α5-/− mice. Patch experiments were performed in neurons near the medial terminal nucleus of the accessory optic tract (MT), where the Ih current typically identifies dopaminergic neurons in mice [41,46]; putative dopaminergic neurons were thus identified by the presence of an Ih current [18,19,42] (Figure 3A). We performed whole-cell voltage clamp recordings at -70 mV, and nAChR currents were elicited by puff application of ACh (1 mM, 300 ms, applied every 2 min) (Figure 3B) in the presence of atropine (1 µM) to block muscarinic acetylcholine receptors. We found that the peak amplitude of the nicotinic current elicited by ACh was significantly smaller in α5-/- neurons (65.1 ± 3.7 pA, n=61 cells across 50 animals) compared to α5+/+ neurons (83.2 ± 5.8 pA, n=57 cells across 45 animals) (two-tailed unpaired t-test, *p<0.01, Figure 3C). We found no difference between the capacitance value of these cells between α5+/+ and α5-/− mice (α5+/+: 7.84 ± 0.4; α5-/−: 7.64 ± 3.8). However the net charge (pA/pF) calculated for these neuronal cells also determined a significant difference (α5+/+: 1.196 ± 0.1938; α5-/−: 0.7455 ± 0.05617; two-tailed unpaired t test, *p<0.05, Figure 3D).

[Image 317x588 to 553x715]

PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e68300
Importantly, almost all evoked nAChR currents were sensitive to the α4* nAChR antagonist dihydro-β-erythroidine (DHβE) (2 µM, 10 min, n=4-6 per genotype, Figure 3 E& F); the percent of baseline current following DHβE application was 25.6 ± 2.5% (n=7 cells across 6 animals) for α5+/+ and 28.4 ± 3.4% (n=7 cells across 6 animals) for α5-/- mice (Figure 3G) (two-tailed unpaired t test, n.s). This confirmed that the ACh-evoked current predominantly reflected α4*-containing receptors, and that α4* currents were reduced in the absence of α5 subunits. Currents with a fast component [18] were rarely observed, and were inhibited by the α7 nAChR antagonist MLA (5 nM, 10 min) in both genotypes (data not shown). In addition, ACh-evoked currents were not reduced by the sodium channel blocker tetrodotoxin (2 µM, 10 min, n=3-5 per genotype, Figure 3K), suggesting that ACh-evoked currents did not reflect changes in presynaptic release and instead represented postsynaptically-evoked nAChR-mediated currents. Finally, repeated ACh puffing led to currents that were stable in amplitude for >20 min in neurons exposed only to aCSF in both α5+/+ (Figure 3H) and α5-/- (Figure 3I), suggesting that ACh-evoked currents did not reflect changes in presynaptic release and instead represented postsynaptically-evoked nAChR-mediated currents. In α5+/+ mice (Figure 3H) and α5-/- mice (Figure 3I), suggesting that this method could reliably be used in subsequent experiments examining changes in nAChR currents with exposure to ethanol and nicotine. The percent of baseline current following 20 min puffing ACh in the presence of aCSF was 106.6 ± 4.3% (n=6 cells across 5 animals) for α5+/+ and 102 ± 7.4% (n=6 cells across 6 animals) for α5-/- mice (Figure 3J) (two-tailed unpaired t test, n.s).

Figure 2. The α4 nAChR is colocalized with TH-positive dopaminergic neurons of the VTA. Representative immunofluorescence images from α5+/+(α4 YFP) (A) and α5-/- (α4 YFP) (B and C); VTA showing α4 nAChR-YFP expression (green), tyrosine hydroxylase (TH) (red) expression, the merged images (green + red) and the colocalization (yellow); VTA showing α4 nAChR-YFP expression (green), GAD65/67 (red), tyrosine hydroxylase (TH) (blue) expression, and the merged images (green + red + blue). Scale bar is 30µm. doi: 10.1371/journal.pone.0068300.g002

Figure 3. The α5 subunit controls the strength of nicotinic currents mediated by the α4*-containing nAChRs in VTA dopaminergic neurons. (A) A typical i_h current. (B) Sample voltage clamp traces of peak inward current of DA neurons to a 300 ms ACh (1mM) puff in α5+/+ (black) and α5-/- mice (gray). (C) The average ACh-induced peak current amplitude was reduced in dopaminergic neurons from α5-/- mice in comparison to α5+/+ mice. (D) The average net charge was reduced in dopaminergic neurons from α5-/- mice in comparison to α5+/+ mice. (E and F) Both α5+/+ (black) (E) and α5-/- (gray) (F) mice showed a nearly complete reduction in the nicotinic currents after 10 min of α4 nAChR antagonist DHβE (2µM) treatment indicating that the responses are mediated by the α4* nAChRs. (G) The percent reduction from baseline following DHβE treatment were similar for α5+/+ and α5-/- mice. (H) Currents were stable to 300ms ACh puffing every 2 min for 20 min in neurons exposed to aCSF in both α5+/+ (black) (H) and α5-/- (gray) (I). (J) There was no significant percent reduction from baseline in both genotypes. (K) TTX (2 µM) had no effect on the current in both α5+/+ and α5-/- mice. In C & D, n = 57-61 cells across 45-50 animals, F, n =7 cells across 6 animals and in I, n=6 cells across 5-6 animals. The values in C are mean peak amplitude ±SEM (two-tailed unpaired t-test, **p<0.01). The values in F&I are reported as mean percent of baseline ±SEM (two-tailed unpaired t-test). The calibrations for the current trace are 100pA, 15 sec (A) and 25pA, 0.5sec (B, E and H).

doi: 10.1371/journal.pone.0068300.g003
α5nAChR subunits reduce receptor desensitization during nicotine exposure

It is well known that nAChRs undergo desensitization, a reversible reduction in current response with prolonged application of an agonist such as nicotine [19,32], including in VTA dopaminergic neurons [19]. Here, we examined the effect of bath application of nicotine (0.3 µM and 1 µM, 10 min) on ACh-induced currents in VTA dopaminergic neurons in slices taken from α5+/+ and α5−/− mice. The average of three ACh-induced current responses (evoked every 2 min across 6 min) was considered as baseline, and responses in the presence of nicotine represented as percent of baseline (see Materials and Methods). Continued exposure to nicotine reduced the amplitude of ACh-induced currents (Figure 4A) in both the α5+/+ and α5−/− neurons, and nAChR desensitization was significantly greater in the absence of the α5 subunit (Figure 4B). Two-way ANOVA analysis of percent reduction from baseline for 0.3 µM nicotine revealed a significant effect of genotype (F(1,128) = 14.05, p<0.001), exposure time (F(7,128) = 32.66, p<0.001) and genotype-time interaction (F(7,128) = 2.15, p<0.05), with post-hoc analysis indicating a greater reduction in α5−/− versus α5+/+ at 10-16 min (Figure 4B). The percent baseline current following 10 min application of 0.3 µM nicotine was 69.2 ± 5% (n=9 cells across 9 animals) for α5+/+ and 47.7 ± 3.4% (n=8 cells across 8 animals) for α5−/− mice (Figure 4C). For the 1 µM dose of nicotine, two-way ANOVA analysis revealed a significant effect of time (F(7,159) = 71.07, p<0.001) and genotype (F(1,159) = 4.13, p<0.05) but no effect on genotype-time interaction (F(7,159) = 1.41, n.s) (α5+/+: 49.9±3.7%, n=10 cells across 9 animals; α5−/−: 36.7±3.8%, n=9 cells across 8 animals).

α5α4* nAChR does not affect ethanol-mediated potentiation of ACh-induced nicotinic current

Ethanol has been shown to potentiate ACh-induced nicotinic currents in cultured neurons [15]. To the best of our knowledge, we demonstrate for the first time that ethanol (60 mM and 80 mM, Figure 5A) can significantly increase the amplitude of ACh-induced currents in VTA dopaminergic neurons of α5+/+ and α5−/− mice. We found no difference in the level of ethanol-induced potentiation of ACh-induced currents in the absence or presence of α5 subunit. A two-way ANOVA analysis revealed a significant effect of 80 mM ethanol exposure time (F(7,128) = 24.96, p<0.001) but no effect of genotype (F(1,128) = 0.77, n.s) or genotype-time interaction (F(7,128) = 0.319, n.s). Post hoc analysis revealed no significant effect (Figure 5B). Similarly, a two-way ANOVA analysis revealed a significant effect of 80 mM ethanol exposure time (F(7,64) = 11.97, p < 0.001) but no effect of genotype (F(1,64) = 1.707, n.s) or genotype-time interaction (F(7,64) = 0.55, n.s) (Figure 5C). The percent of baseline current following 10 min application of 80 mM ethanol was 161.2 ± 11.1% (n=10 cells across 8 animals) for α5+/+ and 149.8 ± 4% (n=8 cells across 6 animals) for α5−/− mice and, for 60mM ethanol application, was 131.8 ± 11.4% (n=7 cells across 5 animals) for α5+/+ and 132.6 ± 12.3% (n=8 cells across 5 animals) for α5−/− mice (Figure 5C).

Discussion

The α4β2* nAChR is widely expressed in the brain and within the ventral tegmental area (VTA) the α5 is an accessory subunit expressed predominantly in α4β2 α5 nAChRs [44,47,48]. There is considerable evidence in in vitro cell-based systems that the inclusion of α5 subunit can regulate the pharmacological properties, Ca2+ permeability and ACh sensitivity of α4β2 nAChR cell lines [30,31,33,49]. Our study is the first ex vivo evidence to show that the α5 nAChR subunit controls α4*-containing nAChR expression in the ventral tegmental area (VTA).

The first level of regulating nAChR expression is the transcription of the subunits. The α5−/− mice were found to have normal transcript levels for all nAChRs subunits, including α4 and β2 in all brain areas including the VTA [35,50]. Although in midbrain dopamine neurons, there is no modulation of α4 and β2 mRNA from birth through adulthood [51], there is a transient increase in α5 mRNA shortly after birth (~p20) which declines through adulthood. In studies involving cell-lines expressed in oocytes, the subunit compositions of nAChRs expressed on the cell surface are dependent on the relative proportions of subunits (cDNAs) available for assembly [52,53]. The inclusion of α5 subunit in the pool with α4 and β2 was shown to increase the number of high binding affinity site measured by [3H] epibatidine in HEK cells compared to the α4β2 parent line [31]. Hence it may be possible that the postnatal surge in α5 mRNA could be facilitating the increase in α4*-containing nAChRs in the midbrain dopamine neurons, there is no modulation of α4 and β2 in all brain areas including the VTA [35,50].
the presence of α5 is consistent with studies involving non-
the VTA of α5+/+ mice. Because of the lack of a5 mRNA in the
knockout mice, the number of α4*-containing nAChRs is
reduced. This is how α5 may influence the assembly of α4*-containing nAChRs in the VTA. The reduced α4 protein levels
measured here could be at the surface or intracellular or both.
Hence determining if this regulation of α4 nAChR subunit
expression has key implication for cholinergic function in the
ventral tegmental area becomes important.

We find that greater number of α4*-containing nAChRs in the
presence of α5 strengthens nicotinic receptor currents in VTA
dopaminergic neurons. Nicotinic currents in both α5+/+ and α5-/- mice were almost fully inhibited by the α4* nAChR
antagonist DHβE, suggesting that the ACh-induced nAChR
currents in VTA dopaminergic neurons were predominantly
mediated by α4*-containing nAChRs, and that the presence of the α5 subunit in the α4* nAChR assembly boosted receptor
currents. A caveat in our study is that electrophysiological
recordings were done in animals between postnatal p21-p28
and the western blot analysis was done in animals between
p35-p70. However previous studies indicate it is unlikely that
there would be any difference in the expression or current
between these two age groups [51,54]. The stronger current in
the presence of α5 is consistent with studies involving non-
nneuronal cell lines where the coexpression of α5 with α4β2
nAChRs produced larger currents than α4β2 alone [30].

Figure 5. The presence of α5α4* nAChR does not affect 
ethanol-mediated potentiation of ACh-induced nicotinic
current. (A) The amplitude of a 300 ms ACh-induced sample
current trace elicited every 2 min during a 10 min exposure to 
ethanol (80 mM) is increased from baseline in neurons from 
α5+/+ (black) and α5−/− (gray) mice. (B) The time course of the 
potentiation of current from baseline for a 10 min exposure of 
80mM ethanol in α5+/+ and α5−/− mice. (C) The average 
percent of baseline current after 10 min of 60 mM and 80 mM 
ethanol exposure for α5+/+ and α5−/− mice. In B&C, n= 5-10 
cells across 5-8 animals. The values in B&C are reported as 
mean percent of baseline ± SEM (two-way ANOVA followed by 
Neuman-Keuls post hoc test). The calibrations for the current 
trace are 25 pA, 0.5 sec.

doi: 10.1371/journal.pone.0068300.g005

Additionally, one brain slice recording study in the prefrontal
cortex showed increases in the amplitude of nicotinic receptor
currents in cortical neurons of α5+/+ mice compared to α5−/− mice [32]. Studies from heterologous cell line suggest that the
inclusion of α5 with α4β2 yield larger currents because of the
formation of higher conductance channel with greater Ca²⁺
permeability [30,49]. Our observation of a critical role for a5 in
maintaining expression of VTA α4* receptors suggests that the
reduced strength of the nicotinic current in the absence of α5 is
likely due to a reduced α4* nAChRs protein levels on the cell
surface. However further molecular studies would be required
to validate surface expression change. One of the functions of
increased Ca²⁺ permeability through nAChR is thought to
increase the excitability of the neuron and modulate
neurotransmitter release [55]. Hence, the reduced nicotinic
current in dopamine neurons is likely to affect excitability in the
α5−/− mice.

The α5 subunit is clearly an important accessory component
of the α4* nAChR assembly in the brain. Moreover, human
genetic association studies have indicated that the minor allele
of rs16969968 in CHRNA5, encoding a single nucleotide polymorphism in the α5 subunit of the nAChR, to be associated
with increased risk of nicotine dependence [21,56] and
association with the level of alcohol response to an alcohol
challenge and dependence [20,23].

The human genetic studies have been complemented well
with behavioral animal studies to show that α5*-containing
nAChRs are important for nicotine [35,36,57]. Additionally,
previous studies have shown the α4*-containing nAChRs to be
important for the reinforcing properties of nicotine [24,58].
Nicotine can increase the release of dopamine neurotransmitter in the striatum facilitating the reward-related
dopamine signal [59,60]. In vitro studies have shown nicotine at high concentrations (or prolonged exposure at low
concentrations) can cause desensitization of nAChRs on
dopaminergic neurons [19,61] and thereby regulating striatal
dopamine release [62]. We found that prolonged exposure to
nicotine at concentrations achieved by smokers [19,63] induces
desensitization of nAChRs on VTA dopaminergic neurons,
which is significantly enhanced in the absence of the a5
subunit. This increased α4 nAChR desensitization in the VTA
dopaminergic neurons likely reduces sensitivity to nicotine and
decreases striatal dopaminergic release, which could explain
the reduced sensitivity to high doses of nicotine [35] and
increased nicotine self-administration [36] in α5−/− mice. These
results about the α5−/− nicotinic receptors become particularly
relevant in understanding the role of CHRNA5 polymorphisms
for nicotine dependence in humans [64–66].

The behavioral role of α5 in ethanol’s effect has been shown to
modulate the sedative effects but not ethanol consumption in
mice [67]. Previous studies have shown ethanol-induced
activation of the VTA DA neurons in vivo and during in vitro
brain slice electrophysiology [6,68]. The interaction of ethanol
with the nAChR ion channel was first demonstrated in Torpedo
nAChRs, where ethanol enhances binding affinity of ACh to
this receptor [69]. Ethanol can potentiate the currents evoked
by ACh in cultured cortical neuronal cells [15,70] and Xenopus
oocytes expressing different subunit compositions nAChRs
α5 subunits with the α4β2* complex [31,44,47]. Hence, the α4*-containing nAChRs participated in ethanol’s potentiation of ACh-evoked current irrespective of the α5 subunit. To the best of our knowledge, this is also the first report of ethanol’s effect on ACh evoked currents in the dopaminergic neurons of the VTA, consistent with oocyte studies showing that α4β2 nAChRs were potentiated with ethanol (75mM) [16,17]. Together, the α5 nAChRs appear to play a key role in the pharmacology of nicotine but not ethanol modulation of nicotinic currents in VTA dopaminergic neurons.

Our observation that α4α5* nAChRs appear to not play a regulatory role in ethanol’s effect is not completely surprising. In behaving animals using null mutant mice of the β2 nAChR subunits [72], α4 nAChR subunits [73] and α5 nAChR subunits [67] found no role in baseline ethanol consumption. In addition, pharmacological manipulation using the α4* nAChR antagonist DHβE showed no effect on ethanol intake [74]. Moreover, recent studies indicate the α3β4* rather than the α4β2* nAChRs may play an important role in regulating ethanol consumption [75]. Although most α5 is likely associated with the α4 subunits, there is also some evidence that the α5 subunit may also be present in α3β4* nAChRs [76], which can also modulate desensitization, pharmacology, Ca2+ permeability of human neuronal α3* nAChRs in recombinant assays and non-neuronal expression systems [76,77]. Nonetheless, most studies indicate a prominent association of α5 subunits with the α4β2* complex [31,44,47].

In conclusion, we have shown the α5 subunit is critical for maintaining the expression of α4* nAChR protein levels of the VTA neurons and strengthening nicotinic currents in dopaminergic neurons. The presence of α5 causes resistance to nicotine desensitization but does not regulate ethanol enhancement of ACh currents in VTA dopaminergic neurons. The α5 nAChR subunit is an important component of the α4* containing nAChRs and plays a vital role for nicotine’s effect in the brain. The α5α4* nAChR appears to be a promising target for at least the treatment for nicotine dependence.

Acknowledgements

We thank Stacy Taylor for excellent technical assistance in weaning and maintaining the breeding colony. We also thank San Francisco Nikon Imaging Center, at the University of California San Francisco for assistance with imaging.

Author Contributions

Analyzed the data: JH CLHK SC. Wrote the manuscript: SC. Conceived the project: SEB AB. Design of the study and development of the manuscript: SC SEB. Performed electrophysiology experiments and analyzed data: SC. Performed biochemistry experiments: JH CLHK VK. Provided critical supplemental content and revisions: SC NS FWH VK SEB. Provided the α4-YFP mice: HL. Provided significant critiques to the manuscript: AB SEB FWH HL. Reviewed contents of the study and have approved final version for publications: SEB SC NS JH CLHK FWH VK HL AB.

References

1. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S et al. (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochim Pharmacol 78: 703-711. doi:10.1016/j.bcp.2009.05.024. PubMed: 19481063.
2. Gotti C, Zoli M, Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27: 482-491. doi:10.1016/j.tips.2006.07.004. PubMed: 16768833.
3. Lindstrom J, Schoepfer R, Conroy WG, Whiting P (1990) Structural and functional heterogeneity of nicotinic receptors. Ciba Found Symp 152: 23-42; discussion 43-52. PubMed: 2209257.
4. Gaimarri A, Moretti M, Riganti L, Zanardi A, Clementi F et al. (2007) Regulation of neuronal nicotinic receptor traffic and expression. Brain Res Rev 55: 134-143. doi:10.1016/j.brainresrev.2007.02.005. PubMed: 17393007.
5. McGehee DS, Role LW (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 57: 521-546. doi:10.1146/annurev.ph.57.030195.002513. PubMed: 759767.
6. Brodie MS, Pesold C, Appel SB (1999) Ethanol directly excites dopaminergic ventral area reward neurons. Alcohol Clin Exp Res 23: 1848-1852. doi:10.1111/j.1530-0277.1999.tb04082.x. PubMed: 10591603.
7. Cornaglia WA, Franklin KB, Coen KM, Clarke PB (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 107: 285-289. doi: 10.1007/BF02245149. PubMed: 1615127.
8. McGehee DS, Patzaff NE, Grady SR, Heinemann SF, Booker TK (2011) Alpha 4beta2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief. J Neurosci 31: 10891-10902.
9. Yang K, Buhman L, Khan GM, Nichols RA, Jin G et al. (2011) Functional nicotinic acetylcholine receptors containing alpha6 subunits are on GABAergic neuronal boutons adherent to ventral tegmental area dopamine neurons. J Neurosci 31: 2537-2548. doi:10.1523/ JNEUROSCI.3003-10.2011. PubMed: 21325221.
10. Guo JZ, Tredway TL, Chiappinelli VA (1998) Glutamate and GABA release are enhanced by different subtypes of presynaptic nicotinic receptors in the lateral geniculate nucleus. J Neurosci 18: 1963-1969. PubMed: 9492789.
11. Livingstone PD, Wonnacott S (2009) Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem Pharmacol 78: 744-755. doi:10.1016/j.bcp.2009.06.004. PubMed: 19523928.
12. Zoli M, Lena C, Picciotto MR, Changeux JP (1998) Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J Neurosci 18: 4461-4472. PubMed: 9614223.
13. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ (1992) A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41: 31-37. PubMed: 1732720.
14. Paterson D, Nordberg A (2000) Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61: 75-111. doi:10.1016/ S0301-0082(99)00045-3. PubMed: 10759066.
15. Aistrup GL, Marszalec W, Narahashi T (1999) Ethanol modulation of nicotinic acetylcholine receptor currents in cultured cortical neurons. Mol Pharmacol 55: 39-49. PubMed: 9882698.
16. Cardoso RA, Brozowski SJ, Chavez-Noriega LE, Harpold M, Valenzuela CF et al. (1999) Effects of ethanol on recombinant human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 289: 774-780. PubMed: 10215652.
17. Yu D, Zhang L, Elisee J-L, Bertrand D, Changeux JP et al. (1996) Ethanol inhibition of nicotinic acetylcholine type alpha 7 receptors involves the amino-terminal domain of the receptor. Mol Pharmacol 50: 1010-1016. PubMed: 8863848.
18. Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA (2003) Differential desensitization and distribution of nicotinic acetylcholine receptor
subtypes in midbrain dopamine areas. J Neurosci 23: 3176-3185.

19. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA (2007) Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390: 401-404. doi:10.1038/37120. PubMed: 9394974.

20. Joslyn G, Brush G, Robertson M, Smith TL, Kalmijn J et al. (2008) Chromosome 15q25.1 genetic markers associated with level of response to alcohol in humans. Proc Natl Acad Sci U S A 105: 20368-20373. doi: 10.1073/pnas.0801970105. PubMed: 19064933.

21. Maozier JR, Collins AC, Corley RP, Hewitt JK et al. (2008) The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol Psychiatry 63: 1039-1046. doi:10.1016/j.biopsych.2007.10.024. PubMed: 18783537.

22. Bierut LJ, Schuckit MA, Hesselbrock V, Reich T (2000) Co-occurring risk factors for alcohol dependence and habitual smoking. Alcohol Res Health 24: 233-241. PubMed: 15986718.

23. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P et al. (2006) Measuring nicotinic receptors with characteristics of α5 nAChR Regulates α4 nAChR Expression in the VTA localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. J Neurosci 23: 11554-11567. PubMed: 14684858.

24. Li S, Misra K, Xiang M (2010) A Cre transgenic line for studying V2 neuronal lineages and functions in the spinal cord. Genesis 48: 67-72. doi:10.1002/dvg.20669. PubMed: 20805657.

25. Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C et al. (2010) Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 12: 299-305. PubMed: 20154679.

26. Mommary JL, Bonci A (2010) Opioid-Induced GABA potentiation after chronic morphine attenuates the rewarding effects of opioids in the ventral tegmental area. J Neurosci 30: 14029-14035. doi: 10.1523/JNEUROSCI.1104-10.2010. PubMed: 20962224.

27. Bonci A, Malenka RC (2000) Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. J Neurosci 19: 3723-3730. PubMed: 10234004.

28. Margolis EB, Lock H, Hjelmstad GO, Fields HL (2006) The Ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons? J Physiol 577: 907-924. doi:10.1113/jphysiol.2006.117069. PubMed: 16959856.

29. Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F et al. (2007) Heterogeneity and complexity of native brain nicotine receptors. Biomed Pharmacol J 74: 1102-1111. doi:10.1155/2007.05.023. PubMed: 17579586.

30. Gotti C, Fornasari D, Clementi F (1997) Human neuronal nicotinic receptors. Prog Neurobiol 53: 189-227. doi:10.1016/S0098-5791(96)00012-X. PubMed: 9384111.

31. Wanat MJ, Hopf FW, Stuber GD, Phillips PE, Bonci A (2008) Corticotropin-releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein kinase C-dependent enhancement of Ih. J Neurophysiol 99: 2157-2170. doi:10.1152/jn.00602-2007. PubMed: 17197101.

32. Mao D, Perry DC, Yasuda RP, Wolfe BB, Kellar KJ (2008) Human α4β2α2β2 nicotinic cholinergic receptor in rat brain is resistant to nicotine in vivo: regulation by nicotinic receptors. Neuroreport 19: 446-456. doi:10.1097/WNR.0b013e3282f2d959. PubMed: 18308824.

33. Perry DC, Xiao Y, Nguyen HN, Musachio JL, Davila-Garcia MI et al. (2002) Measuring nicotine receptors with characteristics of αβ2α2β2α2. Alpha 3beta2alpha2 and alpha3beta2 beta4 subtypes in rat tissues by autoradiography. J Neurochem 82: 468-481.

34. Kuryatov A, Gerzanich V, Nelson M, Otale F, Lindstrom J (1997) Mutation causing autosomal dominant nocturnal frontal lobe epilepsy alters Ca2+ permeability, conductance, and gating of human alpha3beta2alpha2 nicotinic receptors. J Neurosci 17: 9035-9047. PubMed: 9364050.

35. Brown RW, Collins AC, Lindstrom JM, Whiteaker P (2007) Nicotinic α5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. J Neurochem 103: 204-215. doi:10.1111/j.1471-4159.2007.04523.x. PubMed: 17197101.

36. Azam L, Chen Y, Leslie FM (2007) Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons. Neurosci 144: 1347-1360. doi:10.1016/j.neuroscience.2006.11.011. PubMed: 17101001.

37. Moroni M, Bermudez I (2006) Stoichiometry and pharmacology of two human α4β2α2 nicotinic receptor types. J Mol Neurosci 30: 95-96. doi:10.1385/JMNS:30:1:95. PubMed: 17192644.

38. Moroni M, Zwart R, Stief E, Jessel MT, Bermudez I (2006) Alpha 4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol 70: 755-768.

39. Bailey CD, Alves NC, Nashri R, De Biasi M, Lambe MEK (2012) Nicotinic alpha5 subunits drive developmental changes in the activation and morphology of prefrontal cortex layer VI neurons. Biol Psychiatry 71: 120-128. doi:10.1016/j.biopsych.2011.09.011. PubMed: 22030359.

40. Fuente S (2011) Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 51: 1-8. doi:10.1042/CCA20101101. PubMed: 21467366.

41. Bierut LJ, Stitzer MA, Wang JC, Hinichs AL, Grucza RA et al. (2008) Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 165: 1163-1171. doi:10.1176/appi.ajp.2008.07111711. PubMed: 18519524.

42. Fahren S, Slimak MA, Ferrarese L, Santos-Torres J, Antolin-Fontes B et al. (2011) Aversion to nicotine is regulated by the balanced activity of beta4 and alpha5 nicotinic receptor subunits in the medial habenula. Neuron 70: 522-535. doi:10.1016/j.neuron.2011.04.013. PubMed: 21555077.

43. Tapper AR, McKinney SL, Nashri R, Schwarz J, Deshpande P et al. (2004) Nicotine activation of alphaβ2 receptors: sufficient for reward, tolerance, and sensitization. Science 306: 1029-1032. doi:10.1126/science.1099420. PubMed: 15528443.
50. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85: 5274-5278. doi: 10.1073/pnas.85.14.5274. PubMed: 2899326.

51. Rice ME, Cragg SJ (2004) Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 7: 583-584. doi:10.1038/nn1244. PubMed: 15146188.

52. Nisell M, Nomikos GG, Svensson TH (1994) Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 75: 348-352. doi:10.1111/j.1600-0773.1994.tb00373.x. PubMed: 7534921.

53. Zhou FM, Liang Y, Dani JA (2001) Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 4: 1224-1229. doi:10.1038/nn769. PubMed: 11713470.

54. Benowitz NL, Kuyt F, Jacob P 3rd (1982) Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther 32: 758-764. doi:10.1038/clpt.1982.233. PubMed: 7140139.

55. Saccone NL, Wang JC, Breslau N, Johnson EO, Hatsukami D et al. (2009) The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res 69: 6848-6856. doi:10.1158/0008-5472.CAN-09-0786. PubMed: 19706762.

56. Freathy RM, Ring SM, Shields B, Galobardes B, Knight B et al. (2009) A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum Mol Genet 18: 2922-2927. doi:10.1093/hmg/ddp216. PubMed: 19429911.

57. Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC et al. (2009) Human neuronal nicotinic acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob Res 11: 785-796. doi:10.1093/ntr/ntp064. PubMed: 19436041.

58. Santos N, Chatterjee S, Henry A, Holgate J, Bartlett SE (2012) Alpha 5 Neuronal Nicotinic Acetylcholine Receptor Subunit Plays an Important Role in the Sedative Effects of Ethanol But Does Not Modulate Consumption in Mice. Alcohol Clin Exp Res. 69.

59. Blomqvist O, Söderpalm B, Engel JA (1992) Ethanol-induced locomotor activity: involvement of central nicotinic acetylcholine receptors? Brain Res Bull 29: 173-178. doi:10.1016/0361-9230(92)90023-Q. PubMed: 1525672.

60. Forman SA, Righi DL, Miller KW (1989) Ethanol increases agonist affinity for nicotinic receptors from Torpedo. Biochim Biophys Acta 987: 95-103. doi:10.1016/0005-2736(89)90459-8. PubMed: 2597668.

61. Marszałec W, Aistrup GL, Narahashi T (1999) Ethanol-nicotine interactions at alpha-bungarotoxin-insensitive nicotinic acetylcholine receptors in rat cortical neurons. Alcohol Clin Exp Res 23: 439-445. doi:10.1111/j.1530-0277.1999.tb04135.x. PubMed: 10195816.

62. Coventrom PJ, Connolly JG (1997) Differential modulation of rat neuronal nicotinic receptor subtypes by acute application of ethanol. Br J Pharmacol 122: 1661-1668. doi:10.1038/sj.bjp.0701568. PubMed: 9422812.

63. Kamens HM, Andersen J, Picciotto MR (2010) Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl) 208: 613-626. doi:10.1007/s00213-009-1759-1. PubMed: 20072781.

64. Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR (2010) Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci 30: 10169-10176. doi:10.1523/JNEUROSCI.2601-10.2010. PubMed: 20668200.

65. Hendrickson LM, Zhao-Shea R, Tapper AR (2009) Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psychopharmacology (Berl) 204: 563-572. doi:10.1007/s00213-009-1488-5. PubMed: 19247637.

66. Chatterjee S, Steensland P, Simms JA, Holgate J, Cee JW et al. (2010) Partial agonists of the alpha3beta4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology 35: 603-615. PubMed: 21048701.

67. Quick MW, Ceballos RM, Kasten M, McIntosh JM, Lester RA (1999) Alpha 3beta4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons. Neuropharmacology 38: 769-783.

68. Goveanich V, Wang F, Kytayov A, Lindstrom J (1998) alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors. J Pharmacol Exp Ther 286: 311-320. PubMed: 9658574.